Return to homepagePandemic Pact

Risk And Outcomes Of COVID-19 Patients Exposed To Immunosuppressive And Immunomodulatory Agents In British Columbia. A Population-Based Study.

  • Funded by Michael Smith Foundation for Health Research
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Michael Smith Foundation for Health Research

  • Principal Investigator

    Juan Aviña-Zubieta

  • Research Location

    Canada

  • Lead Research Institution

    University of British Columbia

  • Research Priority Alignment

    N/A

  • Research Category

    Epidemiological studies

  • Research Subcategory

    Disease susceptibility

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Other

  • Occupations of Interest

    Unspecified

Abstract

To be better prepared for the second wave of COVID-19 in BC, we need to understand the risk factors influencing contracting the infection and its outcome in infected people, especially in vulnerable people, such as patients with auto-immune diseases, cancer or those with transplants who are being treated with immunosuppressive or immunomodulatory agents (IIA). Patients using IIA for their care have raised fears about being at a greater risk of contracting COVID-19 as these medications lower the immune system. Also, they have uncertainties as IIA are being used to treat COVID-19. In this study, we will assess: The risk of COVID-19 infection among individuals who use IIA in BC, The risk of serious outcomes among COVID-19 patient who use IIA compared to patients who do not use IIA.